These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8251476)

  • 1. Conformation of a heptapeptide substrate bound to protein farnesyltransferase.
    Stradley SJ; Rizo J; Gierasch LM
    Biochemistry; 1993 Nov; 32(47):12586-90. PubMed ID: 8251476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of farnesyltransferase and Ras processing peptidase.
    Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
    Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR studies of novel inhibitors bound to farnesyl-protein transferase.
    Koblan KS; Culberson JC; Desolms SJ; Giuliani EA; Mosser SD; Omer CA; Pitzenberger SM; Bogusky MJ
    Protein Sci; 1995 Apr; 4(4):681-8. PubMed ID: 7613466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation.
    Brown MS; Goldstein JL; Paris KJ; Burnier JP; Marsters JC
    Proc Natl Acad Sci U S A; 1992 Sep; 89(17):8313-6. PubMed ID: 1518863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational analysis of a farnesyltransferase peptide inhibitor, CVIM.
    Carlacci L
    J Comput Aided Mol Des; 2000 May; 14(4):369-82. PubMed ID: 10815773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics.
    Long SB; Hancock PJ; Kral AM; Hellinga HW; Beese LS
    Proc Natl Acad Sci U S A; 2001 Nov; 98(23):12948-53. PubMed ID: 11687658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ras protein p21 processing enzyme farnesyltransferase in chemical carcinogen-induced murine skin tumors.
    Agarwal R; Khan SG; Athar M; Zaidi SI; Bickers DR; Mukhtar H
    Mol Carcinog; 1993; 8(4):290-8. PubMed ID: 8280377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and preliminary characterization of protein-cysteine farnesyltransferase.
    Manne V; Roberts D; Tobin A; O'Rourke E; De Virgilio M; Meyers C; Ahmed N; Kurz B; Resh M; Kung HF
    Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7541-5. PubMed ID: 2217184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A geranylgeranyltransferase for rhoA p21 distinct from the farnesyltransferase for ras p21S.
    Yoshida Y; Kawata M; Katayama M; Horiuchi H; Kita Y; Takai Y
    Biochem Biophys Res Commun; 1991 Mar; 175(2):720-8. PubMed ID: 1902099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate.
    Hightower KE; Huang CC; Casey PJ; Fierke CA
    Biochemistry; 1998 Nov; 37(44):15555-62. PubMed ID: 9799520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.
    Qian Y; Blaskovich MA; Saleem M; Seong CM; Wathen SP; Hamilton AD; Sebti SM
    J Biol Chem; 1994 Apr; 269(17):12410-3. PubMed ID: 8175645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformation of a novel tetrapeptide inhibitor NH2-D-Trp-D-Met-Phe(pCl)-Gla-NH2 bound to farnesyl-protein transferase.
    Bogusky MJ; Culberson JC; Pitzenberger SM; Garsky VM; Wallace A; Pessi A; Koblan KS
    J Pept Res; 1999 Jul; 54(1):66-73. PubMed ID: 10448971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics.
    Nigam M; Seong CM; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1993 Oct; 268(28):20695-8. PubMed ID: 8407887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesylation of p21 Ras proteins in Xenopus oocytes.
    Zhao J; Kung HF; Manne V
    Cell Mol Biol Res; 1994; 40(4):313-21. PubMed ID: 7866432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures.
    Long SB; Casey PJ; Beese LS
    Structure; 2000 Feb; 8(2):209-22. PubMed ID: 10673434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yeast protein farnesyltransferase: steady-state kinetic studies of substrate binding.
    Dolence JM; Cassidy PB; Mathis JR; Poulter CD
    Biochemistry; 1995 Dec; 34(51):16687-94. PubMed ID: 8527442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
    Vogt A; Qian Y; Blaskovich MA; Fossum RD; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Jan; 270(2):660-4. PubMed ID: 7822292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of alpha-subunit of protein farnesyltransferase. Evidence for a catalytic role.
    Andres DA; Goldstein JL; Ho YK; Brown MS
    J Biol Chem; 1993 Jan; 268(2):1383-90. PubMed ID: 8419339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversion of a human tumour cell line containing oncogenic p21ras is associated with a defect in the post-translational processing of the ras protein.
    Tilbrook PA; Paterson HF; Marshall CJ
    Oncogene; 1995 Feb; 10(4):805-9. PubMed ID: 7862461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.